Oral Huzhang Granules for Acute Gouty Arthritis

Sponsor
Shanghai Yueyang Integrated Medicine Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04462666
Collaborator
(none)
267
3
38

Study Details

Study Description

Brief Summary

We designed this study as a double-blind, randomized, controlled clinical trial. The aim of the study is to evaluate the clinical efficacy, safety and control of recurrence rate of acute gouty arthritis

Condition or Disease Intervention/Treatment Phase
  • Drug: Huzhang granule
  • Drug: Etoricoxib
  • Drug: Huzhang granule Placebo
  • Drug: Etoricoxib Placebo
Phase 2

Detailed Description

Gout is a recurrent chronic inflammatory disease caused by monosodium urate (MSU) crystal . Acute gouty arthritis (GA) is the most common first symptom of gout. With the progress of the disease, the frequency of acute attack increases, and joint destruction may occur. The prevalence of hyperuricemia in China was about 13.3%, and the pooled prevalence of gout was 1.1%. Repeated attacks of GA seriously affect the quality of life, resulting in huge economic costs and mental stress. Due to inadequate prevention and treatment, the target of healing gout is often not achieved. In GA, TCM has shown satisfactory therapeutic effect with less adverse effects and minimal toxicity. Huzhang granule (HZG), a Chinese herbal prescription, is a compound preparation with twelve ingredients which has been used in the clinical treatment of gout for over 30 years at the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated to Shanghai University of TCM.Therefore,this double-blind, randomized, controlled clinical trial. will provide high-quality clinical evidences for evaluating the clinical efficacy, safety and control of recurrence rate of Huzhang granule ,a representative prescription for the treatment of acute gouty arthritis , in the treatment of GA.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
267 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Oral Huzhang Granules for Acute Gouty Arthritis: Protocol for a Randomized, Double-blind, Multicenter Clinical Trial
Anticipated Study Start Date :
Jul 1, 2020
Anticipated Primary Completion Date :
Jul 31, 2023
Anticipated Study Completion Date :
Aug 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: HZG intervention

During the 5-day treatment period, participants in the Experimental group will receive 10 sacks of experimental granules. They will be instructed to take two sacks per day, one in the morning and one in the evening, in approximately 30 minutes after the meal.. The placebo etoricoxib will also be taken daily in the morning for 5 days.

Drug: Huzhang granule
Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
Other Names:
  • Chinese Herbal Medicine
  • Drug: Etoricoxib Placebo
    take one capsule per day in the morning, at approximately 30 minutes after the meal.
    Other Names:
  • Chemical drug
  • Active Comparator: Etoricoxib intervention

    During the 5-day treatment period, participants in the Etoricoxib group will receive 5 Etoricoxib capsules. They will be instructed to take one capsule per day in the morning, at approximately 30 minutes after the meal. The placebo HZKL will also be taken daily in the morning for 5 days.

    Drug: Etoricoxib
    take one capsule per day in the morning, at approximately 30 minutes after the meal.
    Other Names:
  • Chemical drug
  • Drug: Huzhang granule Placebo
    Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
    Other Names:
  • Chinese Herbal Medicine
  • Placebo Comparator: Placebo intervention

    During the 5-day treatment period, participants in the Placebo group will receive 10 sacks of placebo HZG. They will be instructed to take two sacks per day, one sack in the morning and one in the evening, at approximately 30 minutes after the meal. And the placebo etoricoxib also be taken daily in the morning for 5 days.

    Drug: Huzhang granule Placebo
    Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
    Other Names:
  • Chinese Herbal Medicine
  • Drug: Etoricoxib Placebo
    take one capsule per day in the morning, at approximately 30 minutes after the meal.
    Other Names:
  • Chemical drug
  • Outcome Measures

    Primary Outcome Measures

    1. Visual Analogue Score (VAS) [Up to 5 days after treatment]

      Visual Analogue Score is an often-used tool to measure subjective phenomena, which has shown good reliability and validity in terms of assessment of pain. In the clinical study of acute gout attack,it can be used as a tool to measure the degree of pain from 0 to 100 mm (with 0 being no pain and 100 being maximum pain)

    Secondary Outcome Measures

    1. Likert scales for the assessment of joint tenderness and swelling [Up to 5 days after treatment]

      Likert scales for the assessment of joint tenderness and swelling is evaluate the inflammatory response and the degree of injury of the joint.Scores range from 1-5, a higher score indicating a severe symptoms on a participant's joint

    2. symptom relief time [Up to 5 days after treatment]

      Symptom relief time is the time when joint pain feels relieved

    3. 36-Item Short Form Survey [Up to 5 days after treatment]

      36-Item Short Form Survey is a health status profile originally designed to measure eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Scoring the 36-Item Health Survey is a two-step process. First, precoded numeric values are recoded per the scoring key in a given table. Note that all items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores represent the percentage of total possible score achieved. In step 2, items in the same scale are averaged together to create the 8 scale scores. another lists the items averaged together to create each scale. Items that are left blank (missing data) are not taken into account when calculating

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Diagnosis of acute gout arthritis as defined by the American College of Rheumatology 1977 preliminary criteria;

    • Male or non-pregnant, non-nursing female;

    • 18-70 years of age;

    • Gout attack less ≤48 hours;

    • In the week before this observation, non-steroidal anti-inflammatory drugs and analgesic drugs and drugs affecting uric acid metabolism were not taken;

    • Subjects capable of giving informed consent;

    Exclusion Criteria:
    • failing to meet the diagnostic criteria;

    • Evidence of uncontrolled concomitant cardiovascular, nervous system,hepatic or gastrointestinal disease. Potential participants who have active concomitant disease can only be eligible after discussion and agreement with the treating medical team;

    • the patient is in critical condition and it is difficult to evaluate the effectiveness and safety of the clinical observation;

    • severe deformity, stiffness and labor loss of patients with advanced arthritis;

    • known allergic to the drug used in this study.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Shanghai Yueyang Integrated Medicine Hospital

    Investigators

    • Study Chair: Jia Zhou, Shanghai Yueyang Integrated Medicine Hospital, Shanghai

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Shanghai Yueyang Integrated Medicine Hospital
    ClinicalTrials.gov Identifier:
    NCT04462666
    Other Study ID Numbers:
    • 2020024
    First Posted:
    Jul 8, 2020
    Last Update Posted:
    Jul 8, 2020
    Last Verified:
    Jul 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Shanghai Yueyang Integrated Medicine Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 8, 2020